NSABP to Study Docetaxel in Operable Breast Cancer

February 1, 1996
Volume 23, Issue 5

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the National Surgical Adjuvant Breast and Bowel Project (NSABP) have announced the initiation of a new clinical trial (B-27) utilizing docetaxel (Taxotere) in women with operable breast cancer.

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the NationalSurgical Adjuvant Breast and Bowel Project (NSABP) have announcedthe initiation of a new clinical trial (B-27) utilizing docetaxel(Taxotere) in women with operable breast cancer.

Randomization will be into three groups: All groups will firstreceive four cycles of Adriamycin and cyclophosphamide (AC). Aftercompletion of AC, group I will have surgery to remove the localtumor; group II will receive four cycles of docetaxel, followedby surgery; group III will have surgery, followed by four cyclesof docetaxel. All groups will take tamoxifen (Nolvadex) for 5years.